NCT02546700 is a Phase 2 clinical trial of Lebrikizumab in Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT02546700?

NCT02546700 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT02546700?

Interventions in NCT02546700: Lebrikizumab, Placebo.

What condition does NCT02546700 study?

NCT02546700 studies Chronic Obstructive Pulmonary Disease.

Is NCT02546700 still recruiting?

NCT02546700 is currently completed. Last updated 6 September 2017.

Last reviewed 2017-09-06 · How we verify

NCT02546700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed Phase 2 Last updated 6 September 2017

What this trial tests

Phase 2 trial testing Lebrikizumab in Chronic Obstructive Pulmonary Disease in 309 participants. Completed in 25 November 2016.

Timeline

30 September 2015

Primary endpoint
25 November 2016

25 November 2016

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	309
Start date	30 September 2015
Primary completion	25 November 2016
Estimated completion	25 November 2016
Sites	66 locations across Denmark, Russia, Hungary, Mexico, Poland, Argentina, Canada, Bulgaria

Drugs / interventions tested

Lebrikizumab (LEBRIKIZUMAB) — full drug profile →
Placebo

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 40 to 80, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.
Tashkin DP, Wechsler ME. · · 2018 · cited 114× · PMID 29403271 · DOI 10.2147/copd.s152291
Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049
Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease.
Rodrigues SO, Cunha CMCD, Soares GMV, Silva PL, et al · · 2021 · cited 61× · PMID 34681202 · DOI 10.3390/ph14100979
Novel Anti-Inflammatory Approaches to COPD.
Cazzola M, Hanania NA, Page CP, Matera MG. · · 2023 · cited 42× · PMID 37408603 · DOI 10.2147/copd.s419056
Emerging pharmaceutical therapies for COPD.
Lakshmi SP, Reddy AT, Reddy RC. · · 2017 · cited 35× · PMID 28790817 · DOI 10.2147/copd.s121416
Targeted therapy in eosinophilic chronic obstructive pulmonary disease.
Fieldes M, Bourguignon C, Assou S, Nasri A, et al · · 2021 · cited 30× · PMID 33855061 · DOI 10.1183/23120541.00437-2020
Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.
Mormile M, Mormile I, Fuschillo S, Rossi FW, et al · · 2023 · cited 24× · PMID 37108417 · DOI 10.3390/ijms24087254
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease.
Cazzola M, Ora J, Cavalli F, Rogliani P, et al · · 2021 · cited 22× · PMID 34475751 · DOI 10.2147/btt.s295409

Verify or expand the search:

Other trials of Lebrikizumab

Trials testing the same drug.

NCT07471932 — A Study of LAD106 in Healthy Adult Participants · Phase 1 · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06243198 — A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants · Phase 1 · completed
NCT05990725 — Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · active not recruiting
NCT05372419 — A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate · Phase 3 · completed

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02546700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 6 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02546700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing